Cantor Fitzgerald reaffirmed their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a research note released on Thursday morning, Benzinga reports. The brokerage currently has a $65.00 target price on the stock.
A number of other equities research analysts have also recently commented on the company. JMP Securities decreased their price target on Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating on the stock in a report on Friday, August 9th. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a research note on Tuesday, May 21st. They set an overweight rating and a $65.00 target price on the stock. Finally, BMO Capital Markets upped their target price on Structure Therapeutics from $83.00 to $100.00 and gave the company an outperform rating in a research note on Friday, June 7th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus target price of $84.63.
Check Out Our Latest Analysis on Structure Therapeutics
Structure Therapeutics Trading Up 2.3 %
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. Sell-side analysts expect that Structure Therapeutics will post -0.94 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in GPCR. Sandia Investment Management LP acquired a new stake in Structure Therapeutics during the second quarter worth approximately $39,000. Quarry LP purchased a new stake in Structure Therapeutics during the 2nd quarter worth $79,000. Sectoral Asset Management Inc. purchased a new stake in Structure Therapeutics during the 4th quarter worth $139,000. ADAR1 Capital Management LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth about $163,000. Finally, Sei Investments Co. bought a new stake in shares of Structure Therapeutics in the 2nd quarter worth about $212,000. 91.78% of the stock is owned by hedge funds and other institutional investors.
About Structure Therapeutics
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
- Five stocks we like better than Structure Therapeutics
- Financial Services Stocks Investing
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- The How and Why of Investing in Gold Stocks
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.